907208-89-3

Usage

Uses

Used in Pharmaceutical Industry:
4-(5-Methyl-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester, 98+% C15H23N3O2, MW: 277.36 is used as an intermediate in the synthesis of various pharmaceuticals for its potential to contribute to the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, 4-(5-Methyl-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester, 98+% C15H23N3O2, MW: 277.36 is utilized as a key component in the production of agrochemicals, such as pesticides and herbicides, due to its ability to enhance the effectiveness and selectivity of these compounds.
Used in Organic Synthesis:
4-(5-Methyl-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester, 98+% C15H23N3O2, MW: 277.36 serves as a valuable building block in organic synthesis, allowing for the creation of a wide range of organic compounds with diverse applications across various industries.

Upstream product

• 72093-07-3 2-methyl-5-chloropyridine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 3510-66-5 2-Bromo-5-methylpyridine 
• 18368-64-4 2-chloro-5-methylpyridine 

Downstream Products

• 104395-86-0 1-(5-methyl-pyridin-2-yl)piperazine 

Relevant academic research and scientific papers

Remarkably Efficient Iridium Catalysts for Directed C(sp2)-H and C(sp3)-H Borylation of Diverse Classes of Substrates

Here we describe the discovery of a new class of C-H borylation catalysts and their use for regioselective C-H borylation of aromatic, heteroaromatic, and aliphatic systems. The new catalysts have Ir-C(thienyl) or Ir-C(furyl) anionic ligands instead of the diamine-type neutral chelating ligands used in the standard C-H borylation conditions. It is reported that the employment of these newly discovered catalysts show excellent reactivity and ortho-selectivity for diverse classes of aromatic substrates with high isolated yields. Moreover, the catalysts proved to be efficient for a wide number of aliphatic substrates for selective C(sp3)-H bond borylations. Heterocyclic molecules are selectively borylated using the inherently elevated reactivity of the C-H bonds. A number of late-stage C-H functionalization have been described using the same catalysts. Furthermore, we show that one of the catalysts could be used even in open air for the C(sp2)-H and C(sp3)-H borylations enabling the method more general. Preliminary mechanistic studies suggest that the active catalytic intermediate is the Ir(bis)boryl complex, and the attached ligand acts as bidentate ligand. Collectively, this study underlines the discovery of new class of C-H borylation catalysts that should find wide application in the context of C-H functionalization chemistry.

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

A class of GPR40 agonist compounds with amide structure, and uses thereof

The present invention relates to a class of amide compounds with a novel structure, and a pharmaceutical composition thereof, wherein the structure of the amide compound is represented by a general formula (I). According to the present invention, the amide compound (I) can regulate GPR40 activity, and can be used for GPR40 activity related diseases such as diabetes and metabolic syndrome. The formula I is defined in the specification.

POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

SULFONIC ACID SALTS OF HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES

The invention relates to sulfonic acid salts of heterocyclylamide-substituted imidazoles, and to solvates and hydrates thereof, to the use thereof for treating and/or preventing diseases, and to use thereof for producing drugs for treating and/or preventi

GLYCINE COMPOUND

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.

Heterocyclylamide-substituted thiazoles, pyrroles and thiophenes

The invention relates to heterocyclylamide-substituted thiazoles, pyrroles and thiophenes and to processes for preparing them, to their use for the treatment and/or prophylaxis of diseases, and to their use for the production of medicaments for the treatm

HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES

The invention relates to heterocyclylamide-substituted imidazoles and methods for the production of the same, to the use thereof for the treatment and/or prophylaxis of diseases, to the use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases, and especially to the use thereof as antiviral agents, especially against cytomegaloviruses.